A

Acetate, cardiovascular effects of in dialysate solution, in dogs, 3:57
Acetate dialysis, role in causing hypotension, bradycardia and syncope during hemodialysis (Clinical Conference), 2:42
Acid-base correction, during hemodialysis, 2:61
Activated carbon, to reduce levels of bacteria and bacterial endotoxin in dialysis fluids, 3:6
Activated partial thromboplastic time, used to calculate variable heparin requirements during hemodialysis (Commentary), 3:81
Acute drug intoxication and extracorporeal intervention (Commentary), 3:39
Adenocarcinoma, renal, *see* Renal adenocarcinoma
Adsorption, of bilirubin by anion exchange resins in vitro, 3:85
  of proteins and platelet adhesion to biomaterials, in dogs and humans, 2:124
Adsorption isotherms, for sulfonated polystyrenes, 3:1
Adsorption kinetics, related to urea capacity of sulfonated polystyrenes, 3:1
Albumin, affects the bilirubin adsorption rate, 3:85
Alterations in platelet and fibrinogen kinetics during left ventricular bypass, 2:10
Aluminum levels, in brain in dialysis dementia syndrome, 3:102
Amino acids, reduction of concentrations by charcoal hemoperfusion, 1:37
An appeal for visual pleasure (editorial), 2:101
Aneurysm formation, as failure mode in secondary vascular access for hemodialysis, 1:44
Antithrombin-III, and inhibition of platelet adhesion to glass, 3:43
Artificial lung, *see* Lung, artificial
Artificial pancreas, *see* Pancreas, artificial
Aspiration pneumonitis, respiratory support with a membrane oxygenator (Clinical Conference), 3:69
Autonomic neuropathy, *see* Neuropathy, autonomic

B

Bacterial counts, in dialysis fluids, 3:6
Bard polycarbonate, potential use as hemofilter, 1:15
β-lipoprotein, and platelet adhesion to glass, 3:43
Bicarbonate, carbon dioxide transport during hemodialysis and, 2:61
  cardiovascular effects of in dialysate solution, in dogs, 3:57
  generation of, from acetate in dialysate solutions, in dogs, 3:57
  transport of during hemodialysis, 2:61
Bilirubin, adsorption of by anion exchange resins in vitro, 3:85
Biocompatibility, of silicone coating of charcoal for hemoperfusion, 3:116
Biomaterials, platelet adhesion to, in dogs and humans, 2:124
Blood access, in hemodialysis with a coaxial counterflow single-needle catheter, 3:33
  line compliance, in extent of recirculation in a single-lumen needle hemodialysis system, 3:29
  platelet adhesion to biomaterials, in dogs and humans, 2:124
Blood-material interactions, as factor in variable heparin requirements during hemodialysis (Commentary), 3:81
  with DEAE cellulose membranes in hemodialysis, 1:24
Blood phase, compliance of, in spiral coil membrane lung, 2:92
Bradycardia, hypotension-induced, during hemodialysis (Clinical Conference), 2:42
Brain aluminum levels, in dialysis dementia syndrome, 3:102
Bypass, left ventricular, problems of left ventricular failure (Commentary), 2:1
  veno-arterial cardiopulmonary, without heparin, in baboons, 2:17

C

Calcium loss, and use of Redy® system in hemodialysis (Commentary), 2:49
Calves, alterations in platelet and fibrinogen kinetics during left ventricular bypass, 2:10
CAPD, *see* Peritoneal dialysis, continuous ambulatory
Capillary permeability, in peritoneal dialysis (Commentary), 1:2
  vasomotion, in peritoneal dialysis (Commentary), 1:2
Carbon dioxide, transport during hemodialysis, 2:61
Cardiac pacing, transvenous, during syncopic episodes during hemodialysis (Clinical Conference), 2:42
  surgery, use of right ventricular assist pump for acute right ventricular failure (Clinical Conference), 3:120
Cardiopulmonary bypass, *see* Bypass
Cardiovascular effects of sodium succinate versus bicarbonate and acetate in dialysate solutions, in dogs, 3:57
Cause of death, in acute renal failure, 3:98
Cellular and humoral immune responses of hemodialysis patients to bivalent influenza vaccination, 3:20
Cellular immunity, *see* Immunity, cellular
Cellulose acetate, potential use as hemofilter, 1:15
Ceruloplasmin, and inhibition of platelet adhesion to glass, 3:43
Charcoal, silicone coated for hemoperfusion, 3:116
Charcoal hemoperfusion, *see* Hemoperfusion, charcoal
Chronic hemodialysis, *see* Hemodialysis, chronic
Chronic uremia, *see* Uremia
Clearance ratio, as a correlation of peritoneal transport rates with molecular weight, 2:107
Clinical experience with continuous ambulatory peritoneal dialysis, 2:114
Clinical left ventricular bypass: problems of pump inflow obstruction and right ventricular failure (Commentary), 2:1
Closed-loop delivery, and remission in juvenile diabetes, 3:133
Coating thickness, of silicone on charcoal for hemoperfusion, 3:116
Coaxial flow, with a single-needle blood access catheter for hemodialysis, 3:33
Collagen, platelet adhesion and thrombus formation on, 2:28
Column disc peritoneal catheter, and improved drainage, in dogs, 3:109
Coma, hepatic, reversal by charcoal hemoperfusion, 1:37
Combination of sulfinpyrazone pretreatment with denucleation priming for membrane oxygenator perfusion in sheep, 2:86
Complications of hemodialysis and peritoneal dialysis in acute renal failure, 3:98

A

Acetate, cardiovascular effects of in dialysate solution, in dogs, 3:57
Acetate dialysis, role in causing hypotension, bradycardia and syncope during hemodialysis (Clinical Conference), 2:42
Acid-base correction, during hemodialysis, 2:61
Activated carbon, to reduce levels of bacteria and bacterial endotoxin in dialysis fluids, 3:6
Activated partial thromboplastic time, used to calculate variable heparin requirements during hemodialysis (Commentary), 3:81
Acute drug intoxication and extracorporeal intervention (Commentary), 3:39
Adenocarcinoma, renal, *see* Renal adenocarcinoma
Adsorption, of bilirubin by anion exchange resins in vitro, 3:85
  of proteins and platelet adhesion to biomaterials, in dogs and humans, 2:124
Adsorption isotherms, for sulfonated polystyrenes, 3:1
Adsorption kinetics, related to urea capacity of sulfonated polystyrenes, 3:1
Albumin, affects the bilirubin adsorption rate, 3:85
Alterations in platelet and fibrinogen kinetics during left ventricular bypass, 2:10
Aluminum levels, in brain in dialysis dementia syndrome, 3:102
Amino acids, reduction of concentrations by charcoal hemoperfusion, 1:37
An appeal for visual pleasure (editorial), 2:101
Aneurysm formation, as failure mode in secondary vascular access for hemodialysis, 1:44
Antithrombin-III, and inhibition of platelet adhesion to glass, 3:43
Artificial lung, *see* Lung, artificial
Artificial pancreas, *see* Pancreas, artificial
Aspiration pneumonitis, respiratory support with a membrane oxygenator (Clinical Conference), 3:69
Autonomic neuropathy, *see* Neuropathy, autonomic

B

Bacterial counts, in dialysis fluids, 3:6
Bard polycarbonate, potential use as hemofilter, 1:15
β-lipoprotein, and platelet adhesion to glass, 3:43
Bicarbonate, carbon dioxide transport during hemodialysis and, 2:61
  cardiovascular effects of in dialysate solution, in dogs, 3:57
  generation of, from acetate in dialysate solutions, in dogs, 3:57
  transport of during hemodialysis, 2:61
Bilirubin, adsorption of by anion exchange resins in vitro, 3:85
Biocompatibility, of silicone coating of charcoal for hemoperfusion, 3:116
Biomaterials, platelet adhesion to, in dogs and humans, 2:124
Blood access, in hemodialysis with a coaxial counterflow single-needle catheter, 3:33
  line compliance, in extent of recirculation in a single-lumen needle hemodialysis system, 3:29
  platelet adhesion to biomaterials, in dogs and humans, 2:124
Blood-material interactions, as factor in variable heparin requirements during hemodialysis (Commentary), 3:81
  with DEAE cellulose membranes in hemodialysis, 1:24
Blood phase, compliance of, in spiral coil membrane lung, 2:92
Bradycardia, hypotension-induced, during hemodialysis (Clinical Conference), 2:42
Brain aluminum levels, in dialysis dementia syndrome, 3:102
Bypass, left ventricular, problems of left ventricular failure (Commentary), 2:1
  veno-arterial cardiopulmonary, without heparin, in baboons, 2:17

C

Calcium loss, and use of Redy® system in hemodialysis (Commentary), 2:49
Calves, alterations in platelet and fibrinogen kinetics during left ventricular bypass, 2:10
CAPD, *see* Peritoneal dialysis, continuous ambulatory
Capillary permeability, in peritoneal dialysis (Commentary), 1:2
  vasomotion, in peritoneal dialysis (Commentary), 1:2
Carbon dioxide, transport during hemodialysis, 2:61
Cardiac pacing, transvenous, during syncopic episodes during hemodialysis (Clinical Conference), 2:42
  surgery, use of right ventricular assist pump for acute right ventricular failure (Clinical Conference), 3:120
Cardiopulmonary bypass, *see* Bypass
Cardiovascular effects of sodium succinate versus bicarbonate and acetate in dialysate solutions, in dogs, 3:57
Cause of death, in acute renal failure, 3:98
Cellular and humoral immune responses of hemodialysis patients to bivalent influenza vaccination, 3:20
Cellular immunity, *see* Immunity, cellular
Cellulose acetate, potential use as hemofilter, 1:15
Ceruloplasmin, and inhibition of platelet adhesion to glass, 3:43
Charcoal, silicone coated for hemoperfusion, 3:116
Charcoal hemoperfusion, *see* Hemoperfusion, charcoal
Chronic hemodialysis, *see* Hemodialysis, chronic
Chronic uremia, *see* Uremia
Clearance ratio, as a correlation of peritoneal transport rates with molecular weight, 2:107
Clinical experience with continuous ambulatory peritoneal dialysis, 2:114
Clinical left ventricular bypass: problems of pump inflow obstruction and right ventricular failure (Commentary), 2:1
Closed-loop delivery, and remission in juvenile diabetes, 3:133
Coating thickness, of silicone on charcoal for hemoperfusion, 3:116
Coaxial flow, with a single-needle blood access catheter for hemodialysis, 3:33
Collagen, platelet adhesion and thrombus formation on, 2:28
Column disc peritoneal catheter, and improved drainage, in dogs, 3:109
Coma, hepatic, reversal by charcoal hemoperfusion, 1:37
Combination of sulfinpyrazone pretreatment with denucleation priming for membrane oxygenator perfusion in sheep, 2:86
Complications of hemodialysis and peritoneal dialysis in acute renal failure, 3:98

Concentration polarization model of hemofiltration with highly permeable membranes, 2:73
Continuous ambulatory peritoneal dialysis, *see* Peritoneal dialysis, continuous ambulatory
Correlation of peritoneal transport rates with molecular weight: a method for predicting clearances, 2:107
Creatinine, adsorption of, and silicone coating of charcoal for hemoperfusion, 3:116
transfer between interstitial and intracellular fluid, 2:35
Cycle time, during continuous ambulatory peritoneal dialysis, 2:54
Cyclic AMP, in reversal of hepatic coma by charcoal hemoperfusion, 1:37
Cystic change in the kidneys of maintenance hemodialysis patients, 3:65
Cystic disease, acquired, in kidneys of maintenance hemodialysis patients, 3:65

D

Demonstration of middle molecules in plasma and brain during experimental acute hepatic encephalopathy, 3:153
Desferrioxamine treatment, in patient with radical nephrectomy (Clinical Conference), 2:133
Determinants of recirculation in a single-lumen needle hemodialysis system, 3:29
Device longevity, in secondary vascular access for hemodialysis, 1:44
Diabetes, juvenile, servo-controlled versus continuous insulin infusion as factor of remission in, 3:133
Dialysate, acidification of, related to urea capacity of sulfonated polystyrenes, 3:1
comparison of cardiovascular effects of sodium succinate versus bicarbonate and acetate, in dogs, 3:57
containing glycerol in hemodialysis, 2:119
in continuous ambulatory peritoneal dialysis, clinical experience, 2:114
peritoneal, mathematical model quantifying mass transfer properties in, 3:140
regeneration of, by urea adsorbent sulfonated polystyrenes, 3:1
Dialysis catheter, indwelling, and improved drainage during peritoneal dialysis, in dogs, 3:109
Dialysis complications, in acute renal failure, 3:98
Dialysis dementia syndrome, report of fourteen cases, 3:102
Dialyzer compliance, in extent of recirculation in a single-lumen needle hemodialysis system, 3:29
Diethylaminoethyl cellulose, evaluation of thrombogenic potential as dialysis membrane, 1:24
1,25-Dihydroxicholecalciferol, in hemodialysis patient (Clinical Conference), 2:133
Disequilibrium syndrome, in hemodialysis with glycerol containing dialysate, 2:119
Disseminated intravascular coagulation, *see* Intravascular coagulation, disseminated
Dissociation constant, to calculate bilirubin adsorption rate by anion exchange resins, in vitro, 3:85
Dogs, drug removal by hemodialysis and hemoperfusion in, 3:39
and humans, comparison of platelet adhesion to biomaterials, 2:124
improved drainage with column disc peritoneal catheter, 3:109
potential source of fixed base in dialysate solutions, 3:57
Donnan ratio, to calculate bicarbonate transport during hemodialysis, 2:61
Drainage volume, during continuous ambulatory peritoneal dialysis, 2:54
Drug removal, by hemodialysis and hemoperfusion, in dogs, 3:39
Dwell time, in continuous ambulatory peritoneal dialysis, 2:114
of dialysis fluid, and peritoneal mass transfer properties, 3:140

E

Editorial, 1:1
Electrolyte control, in continuous ambulatory peritoneal dialysis, 2:114
Encephalopathy, hepatic, demonstration of middle molecules in plasma and brain during, 3:153
Endotoxin, levels in dialysis fluids, 3:6
End-stage renal disease, *see* Renal disease, end-stage
Enhanced efficiency of peritoneal dialysis using rapid, small-volume exchanges, 2:103
Epon, platelet adhesion and thrombus formation on, 2:28
Extracorporeal blood circulation, effect on platelet and fibrinogen during left ventricular bypass, in calves, 2:10
Extracorporeal membrane oxygenation, combination of sulfinpyrazone pretreatment with denucleation priming for, in sheep, 2:86
in patient with aspiration pneumonia and septicemia (Clinical Conference), 3:69

F

Failure modes in secondary vascular access for hemodialysis, 1:44
Fatty acids, non-esterified, removal rates by peritoneal dialysis, 1:8
removal of, during peritoneal dialysis, mechanisms, rates and significance, 1:8
Fibrinogen, influences bovine platelet adhesion, 3:50
kinetics of, in left ventricular bypass, in calves, 2:10
First hemodialyzer, 1:2
Fixed base, potential source of in dialysate solutions, in dogs, 3:57
Fulminant hepatic failure, and plasma middle molecules, in humans, 3:153

G

Galactose oxydase treatment, influences bovine platelet adhesion, 3:50
Gamma-globulin, human, sorption of studied kinetically on quartz, 3:160
influences bovine platelet adhesion, 3:50
Gas transfer performance, of spiral coil membrane lung, 2:92
Gel permeation chromatography, for analysis of plasma and brain middle molecules during experimental acute hepatic encephalopathy, 3:153
Gelatin, platelet adhesion and thrombus formation on, 2:28
Glass, inhibition of platelet adhesion to, by certain human plasma and serum proteins, 3:43
Glutethimide, removal by hemodialysis and hemoperfusion, in dogs, 3:39
Glycerol, in dialysate for hemodialysis, 2:119

Glycoprotein-platelet interaction, as influences on bovine platelet adhesion, 3:50
Graphic work, standards for publication, 2:101

H

Heart, use of assist pump for acute right ventricular failure (Clinical Conference), 3:120
Hemodialysis, bicarbonate and carbon dioxide transport during, 2:61
chronic, and dialysis dementia syndrome, 3:102
with coaxial counterflow single-needle blood access catheter, 3:33
complications of, in acute renal failure, 3:98
creatinine transfer between interstitial and intracellular fluid, 2:35
determinants of recirculation in a single-lumen system, 3:29
with glycerol containing dialysate, 2:119
hemofiltration with highly permeable membranes substituted for, 2:73
intermittent, as factor in hypotension during hemodialysis, 3:11
maintenance, cystic changes of patients on, 3:65
maintenance, development of hypotension, bradycardia and syncope during (Clinical Conference), 2:42
maintenance, variable heparin requirements during (Commentary), 3:81
of nonuremic subjects, precise heparinization for, 3:147
osmolality as factor in hypotension during, 3:11
in patient, with prevention of renal osteodystrophy (Clinical Conference), 2:133
potential source of fixed base in dialysate solution, in dogs, 3:57
removal of bacteria and bacterial endotoxin from dialysis fluids by sorbents, 3:6
responses of patients to bivalent influenza vaccination, 3:20
as therapeutic modality for schizophrenia and psoriasis, 3:147
thrombogenicity of heparin-bound membranes, 1:24
secondary vascular access modes, 1:44
use of Redy® system in (Commentary), 2:49
used for acute drug intoxication, in dogs, 3:39
Hemodilution, with spiral coil membrane lung, 2:92
in veno-arterial cardiopulmonary bypass, in baboons, 2:17
Hemofiltration, concentration polarization model with highly permeable membranes, 2:73
solute rejection of membranes in, 1:15
Hemoperfusion, charcoal, in reversal of hepatic coma, 1:37
to remove bilirubin in vitro, 3:85
silicone coating of charcoal using plasma polymerization techniques and, 3:116
used for acute drug intoxication, in dogs, 3:39
Hemosiderosis, in patient with radical nephrectomy (Clinical Conference), 2:133
Heparin, absence in veno-arterial cardiopulmonary bypass, in baboons, 2:17
bonding of, by hemodialysis membranes, 1:24
leach rate of, by hemodialysis membranes, 1:24
neutralizing activity of, factors causing, during hemodialysis (Commentary), 3:81
requirements, variations during hemodialysis (Commentary), 3:81
variable requirements for, during hemodialysis (Commentary), 3:81
Heparinization, precise, for hemodialysis of nonuremic subjects, 3:147
Hepatic encephalopathy, reversal by charcoal hemoperfusion, 1:37
Hollow fiber artificial kidney, *see* Kidney, hollow fiber artificial
Humoral immunity, *see* Immunity, humoral
Hypernatremia, and use of Redy® system in hemodialysis (Commentary), 2:49
Hypertonic solution, use during continuous ambulatory peritoneal dialysis, 2:54
Hypotension, bradycardia and syncope during hemodialysis (Clinical Conference), 2:42
during hemodialysis, osmolality fall as important pathogenetic factory, 3:11
osmolality as factor in, during hemodialysis, 3:11
Hypotension-induced bradycardia, *see* Bradycardia, hypotension-induced
Hypotensive seizure, *see* Seizure, hypotensive
Hypoxic pulmonary vascular response, respiratory support with a membrane oxygenator (Clinical Conference), 3:69

I

Immunoglobulin, and inhibition of platelet adhesion to glass, 3:43
sorption and desorption rates on quartz: evidence for multiple sorbed states, 3:160
Immunity, cellular, of hemodialysis patients from bivalent influenza vaccination, 3:20
humoral, of hemodialysis patients from bivalent influenza vaccination, 3:20
Influenza vaccination, cellular and humoral immune responses of hemodialysis patients to, 3:20
Inhibition of platelet adhesion to glass by certain human plasma and serum proteins, 3:43
Insulin, servo-controlled versus continuous infusion of, as factor of remission in juvenile diabetes, 3:133
Interaction of plasma proteins with bovine platelets, 3:50
Intermittent hemodialysis, *see* Hemodialysis, intermittent
Interstitial fluid, creatinine transfer, 2:35
Intra-aortic balloon counterpulsation, and use of assist pump for acute right ventricular failure (Clinical Conference), 3:120
Intracellular fluid, creatinine transfer, 2:35
Intravascular coagulation, disseminated, respiratory support with a membrane oxygenator (Clinical Conference), 3:69

J

Junctional stenosis, as failure mode in secondary vascular access for hemodialysis, 1:44
Juvenile diabetes, *see* Diabetes

K

Kidney, cystic change in of hemodialysis patients, 3:65
disease, hypotension, bradycardia and syncope during hemodialysis (Clinical Conference), 2:42
hemodialysis of patient with radical nephrectomy (Clinical Conference), 2:133

hollow fiber artificial, and bicarbonate and carbon dioxide transport, 2:61
removal rates of fatty acids by peritoneal dialysis, 1:8
use of Redy® system in hemodialysis (Commentary), 2:49
Kidney failure, acute, complications of hemodialysis and peritoneal dialysis in, 3:98
Kinetic model, of drug elimination by hemodialysis and hemoperfusion, in dogs, 3:39

L

Langmuir-Hinshelwood sorption behavior, and immunoglobulin sorption and desorption rates on quartz, 3:160
Left ventricular bypass, *see* Bypass
Left ventricular bypass pump, in evaluating platelet and fibrinogen kinetics, in calves, 2:10
in left ventricular failure (Commentary), 2:1
Left ventricular failure, clinical use of bypass pump (Commentary), 2:1
Leukocyte count, in membrane oxygenator perfusion, in sheep, 2:86
Lifespan, of platelet and fibrinogen during left ventricular bypass, in calves, 2:10
Lipolysis, in fatty acid removal by peritoneal dialysis, 1:8
Liver devascularization, and demonstration of middle molecules in plasma and brain, 3:153
Lung, artificial, performance characteristics of spiral coil membrane lung, 2:92

M

Mannitol, as factor in hypotension during hemodialysis, 3:11
of creatinine between interstitial and intracellular fluids, 2:35
Mass transfer, during hemodialysis, 2:61
in human peritoneum, 3:140
Mechanical circulatory assistance, in left ventricular bypass failure (Commentary), 2:1
Membranes, hemofiltration, in solute rejection, 1:15
heparin-bound DEAE cellulose, 1:24
silicone rubber, performance in spiral coil membrane lung, 2:92
polyacrylonitrile, in hemofiltration, 2:73
Membrane oxygenator, extracorporeal, in sheep, 2:86
in veno-arterial cardiopulmonary bypass without heparin, in baboon, 2:17
respiratory support in a patient with aspiration pneumonia and septicemia (Clinical Conference), 3:69
spiral coil, performance characteristics, 2:92
Metabolic acidosis, and use of Redy® system in hemodialysis (Commentary), 2:49
Middle molecules, demonstration of, in plasma and brain during experimental acute hepatic encephalopathy, 3:153
Mitogens, nonspecific, cellular responses of hemodialysis patients with bivalent influenza vaccination to, 3:20

N

Nephrectomy, radical, in patient with solitary kidney (Clinical Conference), 2:133
Nerve conduction studies, in continuous ambulatory peritoneal dialysis, 2:114
Neuraminidase treatment, influences bovine platelet adhesion, 3:50
Neuropathy, autonomic, during hemodialysis (Clinical Conference), 2:42
Nitroprusside infusion, in membrane oxygenation of patient with aspiration pneumonia and septicemia (Clinical Conference), 3:69
Non-esterified fatty acids, removal rates by peritoneal dialysis, 1:8
Non-thrombogenic surface, of heparin-bound DEAE cellulose hemodialysis membranes, 1:24
Nonspecific mitogens, *see* Mitogens, nonspecific

O

Open-loop delivery, and remission in juvenile diabetes, 3:133
Osmolality, as factor in causing hypotension during hemodialysis, 3:11
serum, in hemodialysis with glycerol containing dialysate, 2:119
Osteitis fibrosa, in hemodialysis patient (Clinical Conference), 2:133
Osteomalacia, in hemodialysis patient (Clinical Conference), 2:133
Osteoporosis, in hemodialysis patient (Clinical Conference), 2:133
Outflow obstruction, and the column disc catheter in peritoneal dialysis, in dogs, 3:109
Oxalosis, in kidneys of maintenance hemodialysis patients, 3:65
Oxygenator, *see* Membrane oxygenator

P

Pancreas, artificial, servo-controlled versus continuous insulin infusion as factor of remission in juvenile diabetes, 3:133
Pancreatic enzymes, in fatty acid removal by peritoneal dialysis, 1:8
Parallel plate exchanger, in hemofiltration, 2:73
Parathyroid hormone levels, in patient with radical nephrectomy (Clinical Conference), 2:133
Partial thromboplastin time, for assessment of anticoagulation in hemodialysis of nonuremic subjects, 3:147
Pentobarbital, removal by hemodialysis and hemoperfusion, in dogs, 3:39
Performance characteristics of the spiral coil membrane lung, 2:92
Periodate treatment, influences bovine platelet adhesion, 3:50
Peritoneal clearance, during peritoneal dialysis, in rats, 2:103
Peritoneal dialysis, column disc peritoneal catheter and, in dogs, 3:109
complications of, in acute renal failure, 3:98
continuous ambulatory, clinical experience, 2:114
continuous drainage volumes during, 2:54
correlation of peritoneal transport rates with molecular weight, 2:107
as intracorporeal form of hemodialysis (Commentary), 1:2
using rapid, small-volume exchanges, in rats, 2:103
Peritoneal dialysis solution, vasoactivity (Commentary), 1:2

Peritoneal membrane area, in peritoneal dialysis using rapid, small-volume exchanges, in rats, 2:103
human, mathematical model quantifying mass transfer properties of, 3:140
Peritoneal permeability, of fatty acids by dialysis, 1:8
in peritoneal dialysis using rapid, small-volume exchanges, in rats, 2:103
Peritoneal transport rates, correlation with molecular weight, 2:107
Peritoneum, as hemodialyzer (Commentary), 1:2
Peritonitis, problem of continuous ambulatory peritoneal dialysis, clinical experience, 2:114
Permeability, of human peritoneal membrane in peritoneal dialysis, 3:140
Pharmokinetic model, for control of heparinization in hemodialysis of nonuremic subjects, 3:147
Phenobarbital, removal by hemodialysis and hemoperfusion, in dogs, 3:39
Phosphate binders, and dialysis dementia syndrome, 3:102
Plasma ferritin levels, in patient with radical nephrectomy (Clinical Conference), 2:133
Plasma glucagon, and insulin infusion as factor of remission in juvenile diabetes, 3:133
Plasma polymerization, to silicone coat charcoal for hemoperfusion, 3:116
Plasma proteins, adsorption to biomaterials, in dogs and humans, 2:124
Plasma renin activity, during hemodialysis (Clinical Conference), 2:42
Platelet adhesion, to biomaterials, in dogs and humans, 2:124
to glass by human plasma and serum proteins, 3:43
inhibition of, to glass by certain human plasma and serum proteins, 3:43
on subendothelium, Epon, gelatin and collagen, 2:28
and thrombus formation on subendothelium, epon, gelatin and collagen under arterial flow conditions, 2:28
Platelet aggregation, interaction of plasma proteins and bovine platelets, 3:50
in membrane oxygenation perfusion, in sheep, 2:86
Platelet count, in membrane oxygenator perfusion, in sheep, 2:86
Platelet factor 4, release of as a factor in variable heparin requirements during hemodialysis (Commentary), 3:81
Platelet kinetics, in left ventricular bypass, in calves, 2:10
Platelet release reaction, as induced by subendothelium, Epon, gelatin and collagen, 2:28
Pneumonitis, aspiration, *see* Aspiration pneumonitis
Polyacrylonitrile membrane, *see* Membranes, polyacrylonitrile
Polycystic kidney disease, in maintenance hemodialysis patients, 3:65
Pore dimensions, of hemofiltration membranes, 1:15
Potential source of fixed base in dialysate solutions: a comparison of the cardiovascular effects of sodium succinate versus bicarbonate and acetate, 3:57
Precise heparinization for hemodialysis of nonuremic subjects, 3:147
Prevention of renal osteodystrophy in a patient treated by hemodialysis following abrupt transition from normal to absent renal function (Clinical Conference), 2:133
Primates, need for heparin in cardiopulmonary bypass, in baboons, 2:17
Protein diffusion, in hemofiltration with highly permeable membranes, 2:73
gel buildup, in hemofiltration with highly permeable membranes, 2:73
loss, in continuous ambulatory peritoneal dialysis, 2:114
PTFE vascular prostheses, as secondary vascular access for hemodialysis, 1:44
Pulmonary embolization, septic, respiratory support with a membrane oxygenator (Clinical Conference), 3:69
Pump inflow obstruction, with left ventricular bypass pump (Commentary), 2:1
Pyrogenic reaction, to bacteria and bacterial endotoxin from dialysis fluids, 3:6

Q

Quartz, immunoglobulin sorption and desorption rates on, 3:160

R

Radical nephrectomy, *see* Nephrectomy, radical
Radio frequency discharge, and silicone coating of charcoal for hemoperfusion, 3:116
Radio-labeled heparin, uptake by hemodialysis membrane, 1:24
Rats, peritoneal dialysis using rapid, small-volume exchanges in, 2:103
Recirculation, clinical evaluation of, in single-lumen needle hemodialysis system, 3:29
in hemodialysis with a coaxial counterflow single-needle blood access catheter, 3:33
Red blood cell mass, in creatinine transfer between interstitial and intracellular fluid, 2:35
transfusion, fresh-frozen, in patient with radical nephrectomy (Clinical Conference), 2:133
Redy® or not (Commentary), 2:49
Redy® system, for regeneration of recirculated hemodialysis fluid (Commentary), 2:49
Rejection of solutes by hemofiltration membranes, 1:15
Remission, in juvenile diabetes, servo-controlled versus continuous insulin infusion as a factor of, 3:133
Removal of bacteria and bacterial endotoxin from dialysis fluids by sorbents, 3:6
Renal adenocarcinoma, in cysts in kidneys of maintenance hemodialysis patients, 3:65
in hemodialysis patient (Clinical Conference), 2:133
Renal disease, chronic, Redy® system in hemodialysis (Commentary), 2:49
end-stage, bicarbonate and carbon dioxide transport during hemodialysis, 2:61
continuous ambulatory peritoneal dialysis during, 2:114
hypotension, bradycardia and syncope during hemodialysis (Clinical Conference), 2:42
Renal failure, acute, complications of hemodialysis and peritoneal dialysis in, 3:98
Renal osteodystrophy, in hemodialysis patient (Clinical Conference), 2:133
Renal transplantation, and dialysis dementia syndrome, 3:102
Residual volume, and column disc peritoneal catheter in peritoneal dialysis, in dogs, 3:109
Resin porosity, as factor in bilirubin adsorption during hemoperfusion, in vitro, 3:85

Respiratory distress syndrome, adult, role of membrane oxygenator (Clinical Conference), 3:69
Respiratory support with a membrane oxygenator in a patient with aspiration pneumonia and septicemia (Clinical Conference), 3:69
Reversal of hepatic coma by coated charcoal hemoperfusion: clinical and biochemical observations, 1:37
Rhône Poulenc RP-AN 69, potential use as hemofilter, 1:15
Right ventricular failure, left ventricular failure following cardiotomy and (Commentary), 2:1
use of right ventricular assist pump and (Clinical Conference), 3:120
Right ventricular function, and use of assist pump for right ventricular failure (Clinical Conference), 3:120

S

Saphenous vein graft, as secondary vascular access for hemodialysis, 1:44
Secondary vascular access, *see* Vascular access, secondary
Seizure, hypotensive, during hemodialysis (Clinical Conference), 2:42
Septic pulmonary embolization, *see* Pulmonary embolization, septic
Septicemia, from bacteria and bacterial endotoxin from dialysis solution, 3:6
Serotonin release, interaction of plasma proteins with bovine platelets, 3:50
Serum phosphorus, in patient with radical nephrectomy (Clinical Conference), 2:133
Serum proteins, as inhibitor of platelet adhesion to glass, 3:43
Serum triglycerides, in continuous ambulatory peritoneal dialysis, 2:114
Servo-controlled versus continuous insulin infusion as a factor of remission in juvenile diabetes, 3:133
Sheep, membrane oxygenator perfusion in, 2:86
Silicone, coating, for charcoal for hemoperfusion, 3:116
rubber membranes, *see* Membranes, silicone rubber
Sodium balance, in continuous ambulatory peritoneal dialysis, 2:114
Solutes, rejection by hemofiltration membranes, 1:15
water-soluble, correlation of peritoneal transport rates with molecular weight, 2:107
Sorbent, activated charcoal used as, in hemoperfusion, 1:37
cartridge, to reduce levels of bacteria and bacterial endotoxins in dialysis fluids, 3:6
urea, capacity of sulfonated polystyrenes, 3:1
Sorption of bilirubin by anion exchange resins in vitro, 3:85
Sorption kinetics, of immunoglobulins, on quartz, 3:160
Species differences, in platelet adhesion, in dogs and humans, 2:124
Spectroscopy, internal reflection fluorescence, and study of sorption kinetics of immunoglobulins on quartz, 3:160
Staverman reflection coefficient, in calculating solute rejection by hemofiltration membranes, 1:15
Stirring effects, in peritoneal dialysis using rapid, small-volume exchanges, in rats, 2:103
Subendothelium, platelet adhesion and thrombus formation on, 2:28
Succinate, cardiovascular effects of in dialysate solution, in dogs, 3:57
Sulfonated polystyrene, urea adsorption capacity of, 3:1

T

Tenckhoff catheter, and peritoneal dialysis drainage, in dogs, 3:109
Thrombogenicity of heparin-bound DEAE cellulose hemodialysis membranes, 1:24
Thrombus formation, on subendothelium, Epon, gelatin and collagen, 2:28
Toxic encephalopathy, in dialysis dementia syndrome, 3:102
Transcellular transport, in peritoneal dialysis (Commentary), 1:2
Transport mechanisms, of fatty acids by peritoneal dialysis, 1:8
Transvenous cardiac pacing, *see* Cardiac pacing, transvenous
Turnover, rate of, for platelets and fibrinogen during left ventricular bypass, in calves, 2:10

U

Ultracentrifugation, and effects on inhibition of platelet adhesion to glass by certain human plasma and serum proteins, 3:43
Ultrafiltration, as factor in hypotension during hemodialysis, 3:11
during continuous ambulatory peritoneal dialysis, 2:54
Unipuncture needle hemodialysis system, and coaxial counterflow catheter, 3:33
determinants of recirculation in, 3:29
Urea adsorption capacity of sulfonated polystyrenes, 3:1
Uremia, chronic, removal rates of fatty acids by peritoneal dialysis, 1:8
creatinine transfer between interstitial and intracellular fluids during, 2:35
use of Redy® system in hemodialysis (Commentary), 2:49
Urea sorbent, *see* Sorbent, urea
Urinary C-peptide, and insulin infusion as factor of remission in juvenile diabetes, 3:133
Use of a right ventricular assist pump for acute right ventricular failure (Clinical Conference), 3:120

V

Vacuum priming, for membrane oxygenator perfusion, in sheep, 2:86
Variable heparin requirements during hemodialysis—why? (Commentary), 3:81
Vascular access, secondary, and single-lumen needle hemodialysis system, 3:29
Vascular instability, during hemodialysis, 3:11
Vascular prosthesis, *see* PTFE vascular prosthesis
Vascular stability, in hemodialysis with glycerol containing dialysate, 2:119
Vein graft, *see* Saphenous vein graft
Veno-arterial cardiopulmonary bypass without heparin in the baboon, 2:17
Veno-venous perfusion, in membrane oxygenation of patient with aspiration pneumonia and septicemia (Clinical Conference), 3:69
Venous access sites, in single-lumen needle hemodialysis system, 3:29
Ventilator therapy, in membrane oxygenation of patient with aspiration pneumonia and septicemia (Clinical Conference), 3:69

Ventricular aneurysm, and use of right ventricular assist pump (Clinical Conference), 3:120
Ventricular assist pump, for acute right ventricular failure (Clinical Conference), 3:120
Ventricular failure, *see* Left ventricular failure; *also see* Right ventricular failure

W

Water balance, during continuous ambulatory peritoneal dialysis, 2:54
Water-soluble solutes, *see* Solutes, water-soluble
Water treatment, for removal of trace elements in dialysis, 3:102

Author Index—Volumes 1, 2, 3

A

Abraham, J, 1:8
Aguero, S M, 3:6
Anderson, R D, 2:17
Ash, S R, 3:109

B

Bansal, V K, 3:65
Baumgartner, H R, 2:28
Beissinger, R L, 3:160
Bernard, D B, 2:42
Bernard, J, 3:29
Bernstein, E F, 2:10
Blevins, W, 3:109
Bölük, M Y, 3:116
Borowick, J H, 2:124
Boschat, M, 3:153
Brackett, R G, 3:20
Brain, A J S, 3:98
Brandes, J M, 3:85
Brandon, F B, 3:20
Briggs, W A, 3:20

C

Carey, J, 2:119
Carson, L A, 3:6
Cestero, R V M, 3:29
Chejfec, G, 3:65
Chuang, H Y K, 3:43
Cohan, S L, 1:37
Cohen, I M, 3:33
Cooper, J D, 2:86, 3:69
Cueille, G, 3:153

D

Dammin, G J, 1:44
Daugirdas, J T, 3:65
Delorme, M, 3:153
Denis, J, 3:153
de Veber, G A, 2:114
Dewberry, F L, 3:102
Dhein, C, 3:109
Didisheim, P, 2:124
Dombros, N, 2:114
Duffin, J, 2:86

E

Eberle, K, 1:15

F

Faguer, P, 3:153
Farrell, P C, 2:35, 3:1, 3:39, 3:140
Favero, M S, 3:6
Finklestein, F O, 2:103
Fletcher, J R, 2:17
Fountain, S W, 2:86

G

Galletti, P M, 1:1, 2:92
Gandhi, V C, 3:65
Geis, W P, 3:65
Gelfand, M C, 1:37
Gidden, H E, 1:24
Gonzalez, F M, 3:57
Gotch, F A, 2:61
Grabowski, E F, 2:124
Granger, A, 2:73
Granger, J, 3:109

H

Hameed, J, 3:116
Hano, J E, 3:65
Hartman, J, 3:109
Henderson, L W, 2:49
Hirszel, P, 1:8, 2:107
Hohnadel, D C, 1:8
Holland, F F, 1:15, 1:24
Hone, P W E, 3:1
Hsu, C H, 3:98

I

Ing, T S, 3:65

J

Jaffrin, M Y, 2:73
Johnson, H, 3:109

K

Keshaviah, P, 3:29
Kim, S W, 3:50
Kirkendol, P L, 3:57
Kjellstrand, C M, 3:11
Klahr, S, 2:133
Klein, E, 1:15, 1:24
Kliger, A S, 2:103
Knepshield, J H, 1:37
Koszuta, J, 3:109

L

Lasrich, M, 1:8, 2:107
Lazarus, J M, 1:44
Lee, E S, 3:50
Leonard, E F, 3:160
Lindsay, R M, 3:81

M

Mahajan, S K, 3:20
Maher, J F, 1:8
Maher, J M, 2:107
Mahoney, J F, 2:35
Marshall, Jr, J H, 3:6
Martin, B A, 2:86
Marzec, U M, 2:10
Mason, R G, 1:24, 3:43
McDonald, F D, 3:20
McKee, A E, 2:17
McKinney, T D, 3:102
Meyer, R, 2:119
Mirouze, J, 3:133
Mohammad, S F, 3:43
Moncrief, J W, 2:54, 2:114
Mor, L, 3:85
Morgan, A P, 1:44
Muggli, R, 2:28
Murphy, W R C, 2:92
Murrin, C, 2:119

N

Nolph, K D, 1:2, 2:54, 2:114

O

Ogden, D A, 3:33
Opolon, P, 3:153
Oreopoulos, D G, 2:114
Özdural, A R, 3:116

P

Paar, G V S, 3:120
Pearson, J E, 3:57
Petersen, N J, 3:6
Pham, T C, 3:133
Pierce, W S, 2:1
Piskin, E, 3:116
Popovich, R P, 2:54, 2:114
Prowant, B, 2:54

R

Randerson, D H, 3:140
Richardson, P D, 2:92, 2:101
Robson, M, 2:114
Rosa, A A, 3:11
Rozek, R J, 3:20
Rubin, J, 2:54, 2:114

S

Sargent, J A, 2:61
Schindhelm, K, 2:35
Schreiner, G E, 1:37
Selam, J, 3:133
Sell, L, 3:109
Sharma, N C, 3:43
Shideman, J R, 3:11
Shillis, J L, 3:20
Shoor, P M, 2:10
Sideman, S, 3:85
Skalsky, M, 2:35
Stone, W J, 3:102
Stropp, J Q, 2:124
Swamy, A P, 3:29
Swartz, R D, 3:98

T

Thornhill, J A, 3:109
Turitto, V T, 2:28

V

Valk, T W, 3:98
Van Stone, J C, 2:119
Vantard, G, 2:73

W

Ward, C A, 2:86
Ward, R A, 2:147
Wathen, R L, 3:147
Watson, L P, 2:17
Winchester, J F, 1:37

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION
(Act of August 12, 1970: Section 3685. Title 39. United States Code)

Date of Filing—September 27, 1980
Title of Publication—asaio Journal
Frequency of Issue—Quarterly
Annual Subscription Price—$28.00
Location of Known Office of Publication—ASAIO, P.O. Box 777, Boca Raton, FL 33432
Location of the Headquarters or General Business Offices of the Publishers—ASAIO, P.O. Box 777, Boca Raton, FL 33432
Publisher—American Society for Artificial Internal Organs, Inc., P.O. Box 777, Boca Raton, FL 33432
Editor—Pierre M. Galletti, M.D., 36 Taber Avenue, Providence, RI 02906
Managing Editor—Katherine Subramanian, J. B. Lippincott Co., East Washington Square, Philadelphia, PA 19105
Owner—American Society for Artificial Internal Organs, Inc., P.O. Box 777, Boca Raton, FL 33432
Known Bondholders, Mortgagees and other security holders owning or holding 1 per cent or more of total amounts of bonds, mortgages or other securities—None

	Average No. Copies Each Issue during Preceding 12 Months	Actual No. of Copies of Single Issues Published Nearest to Filing Date
A. Total no. copies printed (*net press run*)	1,833	1,850
B. Paid circulation		
1. Sales through dealers and carriers, street vendors and counter sales	88	95
2. Mail subscriptions	1,325	1,338
C. Total paid circulation	1,413	1,433
D. Free distribution by mail, carrier or other means. Samples, complimentary, and other free copies	123	98
E. Total distribution (*sum of C and D*)	1,536	1,531
F. Copies not distributed		
1. Office use, leftover, unaccounted, spoiled after printing	297	319
2. Returns from news agents	—	—
G. Total (*sum of E & F—should equal net press run shown in A*)	1,833	1,850

I certify that the statements made by me above are correct and complete.

Karen K. Burke, Executive Director, ASAIO